Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-0805 in Parkinson's Disease
NCT04127695Phase 1Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Mar 2020
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of exidavnemab in Parkinson's disease (PD) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events, Maximum Observed Serum Concentration and 4 more. Planned start Mar 2020; status: withdrawn.
02
Drugs
exidavnemab
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04127695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04127695.